The ABPI is delighted to welcome a new pharmaceutical company to its thriving membership organisation. As a world leader in diabetes, Novo Nordisk has taken the decision to join the full service trade body for the first time in its history.
Novo Nordisk has been in diabetes for a unique 90 years and holds the largest share of the diabetes market worldwide with a promising future secured by a strong R&D pipeline, not only in diabetes, but also in haemophilia and other bio-pharm medicines.
Peter Meeus, UK General Manager of Novo Nordisk, explains the reasons behind their decision to join:
"As a growing player in the UK pharmaceutical market, we felt the time was right to join the ABPI. The ABPI has undergone real transformation in recent years and we are confident that as our business continues to grow in the UK, ABPI engagement will complement what we are doing to ensure we are better positioned to face the challenges and the opportunities in an increasingly dynamic business setting for the UK pharmaceutical industry."
Stephen Whitehead, Chief Executive of the ABPI, welcomed Novo Nordisk’s decision to join the ABPI:
"Novo Nordisk is a very welcome and important addition to our membership and will further strengthen the ABPI as the voice of the pharmaceutical industry. Novo Nordisk has joined a full service membership organisation that continues to shape the environment to make the UK an attractive destination for the research and development of life changing medicines. We will be looking to support them and our wider membership to ensure that once a medicine has been approved for use in the UK, the NHS is able to adopt it and patients can fully realise its benefits."
ABPI Press OfficeTel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064 Email: [email protected]